Hematologic Malignancy
Primary Cutaneous Lymphoma
CI-CAN-00003736Explore in graph →
Hematologic67 active trials10 approved drugs
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00003736Explore in graph →
Clinical trials
353 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (77)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01728805 | Study of KW-0761 Versus Vorinostat in Relapsed/Refractory CTCL | completed | Phase 3 | 372 | Kyowa Kirin, Inc.INDUSTRY | 11 | Apr 25, 2024 | clinicaltrials |
| NCT02448381 | FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) | completed | Phase 3 | 169 | SoligenixINDUSTRY | 1 | Apr 15, 2022 | clinicaltrials |
| NCT01578499 | A Phase 3 Trial of Brentuximab Vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Participants With CD30-Positive Cutaneous T-Cell Lymphoma (ALCANZA Study)(ALCANZA) | completed | Phase 3 | 131 | Millennium Pharmaceuticals, Inc.INDUSTRY | 12 | Jan 5, 2021 | clinicaltrials |
| NCT00799461 | Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications | completed | Phase 3 | 1,337 | Fred Hutchinson Cancer Research Center/University of Washington Cancer ConsortiumOTHER | 1 | Mar 7, 2012 | clinicaltrials |
Data updated 22 days agoSource updated Apr 25, 2024source: clinicaltrials